Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis has entered into an agreement to sell the US rights to market Enablex (darifenacin) extended release tablets, a medicine to treat adults with symptoms of overactive bladder, to Warner Chilcott.
Subscribe to our email newsletter
As per the terms of the deal, Warner Chilcott assumes rights to solely promote and develop Enablex for the US. While, Novartis retains the rights to Darifenacin worldwide, except in the US.
Warner Chilcott is expected to pay as sum of $400m as an upfront payment to Novartis, with the potential for additional milestone payments up to $20m.
Warner Chilcott expects to assume manufacturing of Enablex for the US once it is transferred to Warner Chilcott’s manufacturing facility.
Enablex was approved in the US by the US Food and Drug Administration in 2004 for the treatment of overactive bladder and launched in early 2005.